Financial Performance - The company's operating revenue for the first half of 2022 was CNY 6,415,750,711.68, a slight increase of 0.16% compared to CNY 6,405,785,343.88 in the same period last year[21]. - The net profit attributable to shareholders of the listed company decreased by 64.33% to CNY 122,025,277.85 from CNY 342,088,698.57 year-on-year[21]. - The net profit after deducting non-recurring gains and losses was CNY 110,053,333.66, down 44.72% from CNY 199,077,310.22 in the previous year[21]. - The total revenue for the reporting period was CNY 6,415,750,711.68, a slight increase of 0.16% compared to the previous year, while operating costs decreased by 0.27% to CNY 4,912,718,059.43[65]. - The net profit for the first half of 2022 was CNY 146,663,962.57, down from CNY 365,615,681.29 in the same period of 2021, reflecting a decrease of approximately 60%[186]. - The total comprehensive income for the first half of 2022 was CNY 145,592,026.94, down from CNY 363,589,260.82 in the first half of 2021[194]. Cash Flow and Liquidity - The net cash flow from operating activities was CNY 165,171,692.83, an increase of 3.60% compared to CNY 159,437,052.40 in the same period last year[21]. - The company’s cash and cash equivalents increased by 33.24% to CNY 2,121,353,318.33, enhancing liquidity[65]. - The company reported a significant increase in cash flow from financing activities, indicating a stronger liquidity position moving forward[199]. - Cash inflow from financing activities reached $1,129,361,541.20, up from $863,205,638.57, with a net cash flow of $279,404,398.56 compared to a negative $53,029,020.84 last period[199]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 12,958,497,615.73, reflecting a 0.90% increase from CNY 12,842,438,765.28 at the end of the previous year[21]. - The total liabilities decreased slightly to CNY 8,373,836,303.86 from CNY 8,421,954,031.68, a reduction of about 0.6%[177]. - Current assets totaled CNY 8,968,958,540.13, up from CNY 8,733,006,005.16, indicating an increase of about 2.7%[175]. - The company reported a decrease in short-term borrowings to CNY 2,252,856,035.88 from CNY 2,077,702,561.19, indicating an increase of about 8.4%[175]. Research and Development - Research and development expenses increased by 24.72% to CNY 52,340,518.52, reflecting the company's commitment to enhancing its R&D capabilities[65]. - The company has over 20 product projects in the research phase, covering multiple therapeutic areas, with ongoing efforts to enhance the quality management system for drug development[50]. - The company has successfully completed the consistency evaluation for two products, with five additional products currently under review, indicating a proactive approach to regulatory compliance[50]. Market and Competitive Position - The pharmaceutical industrial sector faced challenges due to the impact of COVID-19, leading to a strategic adjustment in channel layout and product structure[23]. - The pharmaceutical commercial sector experienced a decline in sales revenue due to national cost control policies and the impact of repeated COVID-19 outbreaks in Heilongjiang province[23]. - The company aims to enhance its market competitiveness by leveraging its brand advantages and product resources, with 70 exclusive products and 280 products listed in the national medical insurance directory[39]. - The company is actively expanding new channels and increased market investment to enhance product competitiveness and terminal market maintenance[37]. Environmental Compliance and Social Responsibility - The company reported actual emissions of 0.815 mg/L for a major pollutant in the first half of 2022, which is below the permitted discharge limit of 12 mg/L[110]. - The company has conducted environmental risk assessments and established a comprehensive environmental risk prevention mechanism[120]. - The company has donated a total of 23.53 million yuan in charitable activities, benefiting over 470,000 individuals across eight provinces[125]. - The company is actively involved in poverty alleviation and rural revitalization efforts, guiding impoverished households to increase their income through agricultural projects[128]. Governance and Management - Key management changes included the resignation of four executives, including the former general manager, and the election of new members to the board of directors[94][99]. - The company reported a significant focus on strategic decision-making and governance, with the establishment of new committees to enhance oversight[95]. - The company emphasized the importance of compliance with legal and regulatory requirements in its governance practices[93].

Financial Performance - In 2021, the company reported a net profit of -130,174,518.92 CNY, resulting in a total distributable profit of -1,968,846,471.28 CNY, leading to no profit distribution for the year[7]. - The company did not extract statutory surplus reserves for the year, as the distributable profit was negative[7]. - The company achieved operating revenue of 12.80 billion RMB, an increase of 18.66% year-on-year[23]. - The net profit attributable to shareholders was 371.08 million RMB, a significant recovery from a loss of 1.08 billion RMB in the previous year[23]. - The net profit after deducting non-recurring gains and losses was 216.93 million RMB, compared to a loss of 714.94 million RMB in 2020[23]. - The weighted average return on equity increased to 10.13%, up 34.25 percentage points from -24.12% in 2020[24]. - The total assets at the end of 2021 were 12.84 billion RMB, reflecting an 8.40% increase from the previous year[23]. - The company reported a net cash flow from operating activities of -162.44 million RMB, an improvement from -728.15 million RMB in 2020[23]. - The basic earnings per share for 2021 was 0.15 RMB, recovering from -0.43 RMB in 2020[24]. - The company’s net assets attributable to shareholders increased by 10.56% to 3.85 billion RMB by the end of 2021[23]. Operational Highlights - The pharmaceutical industrial revenue was 3.46 billion RMB, while the pharmaceutical commercial revenue was 9.28 billion RMB[35]. - The company’s industrial segment saw a year-on-year sales volume increase of 26.2%, significantly boosting sales revenue[36]. - Gross profit margin improved by 7.26% compared to the same period last year, leading to a substantial increase in profitability for 2021[36]. - Non-recurring gains included compensation of 211.14 million yuan from the disposal of idle assets by a subsidiary[36]. - The company is focusing on product marketing by enhancing brand influence and expanding online sales channels, establishing long-term strategic partnerships with major e-commerce platforms[37]. - The company is advancing product development in key therapeutic areas such as neurology, oncology, pediatrics, and respiratory diseases, with several products passing consistency evaluations[39]. - The company has established seven core manufacturing bases to strengthen its product and capacity advantages, including antibiotic raw materials and formulations[39]. Market and Industry Trends - In 2021, the pharmaceutical manufacturing industry in China achieved a revenue of 2,928.85 billion yuan, with a year-on-year growth of 20.1%[40]. - The total profit of the pharmaceutical manufacturing industry reached 627.14 billion yuan, marking a year-on-year increase of 77.9%[40]. - The health supplement market is expanding rapidly, driven by consumer trends towards wellness, with the company leveraging its brand advantages to enhance product offerings[90]. - The new medical reform policies have led to the institutionalization of volume-based procurement, with the updated medical insurance catalog including 2,860 types of drugs[90]. - The pharmaceutical industry is expected to benefit from ongoing supply-side structural reforms, with companies possessing independent innovation capabilities positioned for competitive advantage[87]. Research and Development - Research and development expenses increased by 5.63% to 97.73 million RMB due to the rise in R&D projects[52]. - The company has established a key laboratory for traditional Chinese medicine quality research, enhancing its R&D capabilities[51]. - The company holds 1,804 drug approvals and 86 health product approvals, with 69 exclusive drugs[51]. - R&D investment amounted to 147 million RMB, an increase of 19.17% year-on-year, representing 1.15% of total revenue and 4.23% of the pharmaceutical industry revenue[76]. - The company’s R&D projects are at various stages, with some still in the early research phase, leading to lower overall R&D spending compared to competitors[111]. Risk Management - There were no significant risks that materially affected the company's operations during the reporting period[9]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[8]. - The company focuses on compliance and risk prevention to ensure stable and high-quality development amidst regulatory pressures and market competition[47]. - The company acknowledges R&D risks due to high investment, long cycles, and low success rates in the pharmaceutical industry[133]. - The company is exposed to raw material procurement risks, with rising costs influenced by macroeconomic factors and international energy prices[133]. Corporate Governance - The company maintains full independence in operations, assets, and finances, with no reliance on the controlling shareholder[141]. - Independent directors account for over one-third of the board, enhancing decision-making processes[141]. - The company has established four specialized committees to strengthen board governance and ensure healthy development[141]. - The company has implemented strict confidentiality measures regarding insider information, with no leakage incidents reported[141]. - The company has successfully conducted multiple shareholder meetings, with all resolutions passed in compliance with legal and regulatory requirements[144]. Employee and Management Compensation - The total pre-tax remuneration for the entire management team during the reporting period was 2,101,670 RMB[153]. - The company has implemented a market-oriented compensation system for employees and senior management, emphasizing performance-based incentives and strict control of labor costs[181]. - The company has conducted two meetings of the remuneration and assessment committee, focusing on the review of incentive plans and performance management[181]. - The company’s board of directors has approved the stock option and restricted stock incentive plan for 2021[181]. - The total number of shares held by the management team at the beginning of the year was 505,500 shares, and at the end of the year, it was 4,855,500 shares, reflecting a significant increase[153].

证券代码:600664 证券简称:哈药股份 编号:临 2022-036 哈药集团股份有限公司 关于参加"2022 年投资者网上集体接待日 活动暨业绩说明会"的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担个别及连带责任。 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广大 投资者沟通交流，进一步提升投资者关系管理水平，黑龙江省上市公司协会联合深 圳市全景网络有限公司，将于 2022 年 5 月 12 日 14:30-16:30 在"全景路演" （https://rs.p5w.net/html/132395.shtml）举办"黑龙江省上市公司 2022 年投 资者网上集体接待日活动暨业绩说明会"。 出席本次活动人员有：公司总经理、财务负责人、董事会秘书。（如遇特殊情 况，参与人员可能会有调整，公司不再另行公告。） 为充分尊重投资者、提升交流的针对性，现就公司本次活动提前向投资者公开 征集问题，广泛听取投资者的意见和建议。投资者可于2022年5 月12 日12:00 前 访问 https://ir.p5w.net/zj ...

Financial Performance - The company's operating revenue for Q1 2022 was ¥3,333,837,987.01, representing an increase of 11.88% compared to the same period last year [6] - The net profit attributable to shareholders of the listed company was ¥100,446,359.10, reflecting a growth of 21.21% year-on-year [6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥96,805,205.77, which is an increase of 88.58% compared to the previous year [6] - The basic earnings per share for the period was ¥0.04, up by 33.33% year-on-year [6] - Operating profit for Q1 2022 was CNY 160,484,032.82, up 20.6% from CNY 133,031,105.84 in Q1 2021 [31] - The total cost of operations for Q1 2022 was CNY 3,175,613,101.54, an increase of 10.4% from CNY 2,878,452,857.75 in Q1 2021 [28] - The total comprehensive income attributable to the parent company's owners for Q1 2022 was ¥100,715,949.51, compared to ¥82,744,240.91 in Q1 2021, representing an increase of approximately 21.5% [33] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,764,203,877.95, a decrease of 0.61% from the end of the previous year [8] - Total liabilities decreased to CNY 8,233,515,215.76 from CNY 8,421,954,031.68, a reduction of approximately 2.2% [28] - Total equity increased to CNY 4,530,688,662.19 from CNY 4,420,484,733.60, reflecting a growth of about 2.5% [28] - The company's total assets amounted to CNY 12,764,203,877.95, a slight decrease from CNY 12,842,438,765.28 [28] Cash Flow - The net cash flow from operating activities was ¥154,882,854.26, with a year-on-year comparison deemed not applicable [6] - Cash inflow from operating activities totaled ¥3,277,424,882.21 in Q1 2022, compared to ¥3,050,042,798.87 in Q1 2021, reflecting an increase of about 7.4% [33] - The net cash flow from operating activities for Q1 2022 was ¥154,882,854.26, a significant improvement from a net outflow of ¥173,741,428.63 in Q1 2021 [33] - Cash inflow from investment activities was ¥43,844,524.34 in Q1 2022, compared to ¥1,585,891.74 in Q1 2021, showing a substantial increase [34] - The net cash flow from investment activities for Q1 2022 was ¥11,988,054.23, recovering from a net outflow of ¥13,774,017.34 in Q1 2021 [34] - Cash inflow from financing activities in Q1 2022 was ¥583,415,780.00, down from ¥810,974,027.78 in Q1 2021, indicating a decrease of approximately 28.0% [34] - The net cash flow from financing activities for Q1 2022 was -¥5,098,076.67, compared to a positive net flow of ¥65,951,861.77 in Q1 2021 [34] - The ending balance of cash and cash equivalents as of Q1 2022 was ¥1,753,711,206.00, up from ¥775,151,835.18 at the end of Q1 2021, representing an increase of approximately 126.5% [34] Shareholder Information - Total number of common shareholders at the end of the reporting period is 112,222, with the largest shareholder, Harbin Pharmaceutical Group Co., Ltd., holding 1,173,237,023 shares, accounting for 46.56% [16] - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., has pledged 926,857,248 shares [16] - There are no known related party transactions among the top shareholders [18] Research and Development - Research and development expenses for Q1 2022 were CNY 24,582,703.64, an increase of 9.7% compared to CNY 22,420,110.21 in Q1 2021 [29] Inventory and Receivables - The company experienced a decrease in other receivables by 44.04%, primarily due to repayments received [12] - Accounts receivable reached ¥4,199,524,541.69, up from ¥3,954,581,442.97 year-over-year, indicating a growth of approximately 6.2% [19] - Inventory decreased to ¥1,753,680,748.74 from ¥2,063,793,602.49, reflecting a reduction of about 15% [23] Other Information - The company has not disclosed any significant new product developments or market expansion strategies in the current report [18] - The company reported a decrease in other comprehensive income, with a net amount of CNY 269,590.41 compared to a loss of CNY 125,541.80 in Q1 2021 [31] - The company maintained a stable level of long-term borrowings at CNY 34,306,712.35, showing a minor increase from CNY 34,086,428.35 [28] - The company reported a significant decrease in cash outflow for employee payments, which was ¥394,603,625.37 in Q1 2022, down from ¥499,184,526.40 in Q1 2021, a reduction of about 20.9% [33]

Financial Performance - In 2021, the company reported a net profit of -130,174,518.92 CNY, resulting in a total distributable profit of -1,968,846,471.28 CNY, leading to no profit distribution for the year[7]. - The company achieved operating revenue of 12.80 billion yuan, an increase of 18.66% year-on-year[23]. - The net profit attributable to shareholders was 371.08 million yuan, a significant recovery from a loss of 1.08 billion yuan in the previous year[23]. - The net profit after deducting non-recurring gains and losses was 216.93 million yuan, compared to a loss of 714.94 million yuan in 2020[23]. - The weighted average return on net assets was 10.13%, up from -24.12% in the previous year, indicating a strong recovery[24]. - The company reported a net cash flow from operating activities of -162.44 million yuan, an improvement from -728.15 million yuan in 2020[23]. - The total assets increased by 8.40% to 12.84 billion yuan compared to the end of 2020[23]. - The company’s net assets attributable to shareholders rose by 10.56% to 3.85 billion yuan at the end of 2021[23]. - The basic earnings per share were 0.15 yuan, recovering from a loss of 0.43 yuan per share in 2020[24]. - The gross profit margin improved by 7.26% compared to the same period last year, leading to a substantial increase in profitability for 2021[36]. Risks and Challenges - There were no significant risks that materially affected the company's operations during the reporting period[9]. - The company has outlined various risks and countermeasures in its future development discussion[9]. - The company faces risks from industry policy changes, which may impact its future development due to ongoing healthcare reforms[135]. - The company is exposed to R&D risks, including high investment, long cycles, and low success rates in drug development[135]. - The company is at risk of rising raw material costs due to macroeconomic inflation and other external factors[135]. - The company will closely monitor the pandemic situation and adjust production and sales measures accordingly to mitigate impacts[135]. Corporate Governance - The company maintains full independence in operations, assets, and finances, with no reliance on the controlling shareholder[141]. - Independent directors account for over one-third of the board, enhancing decision-making processes[141]. - The company has established four specialized committees to strengthen board governance and ensure healthy development[141]. - The company has implemented strict confidentiality measures regarding insider information, with no leakage incidents reported[141]. - The company has successfully conducted multiple shareholder meetings, with all resolutions passed in compliance with legal and regulatory requirements[144]. - The company has a comprehensive information disclosure system, ensuring timely and accurate communication with shareholders[141]. Research and Development - The company is focusing on product marketing by enhancing brand influence and expanding online sales channels, establishing long-term strategic partnerships with major e-commerce platforms[37]. - The company is advancing product development in key therapeutic areas such as neurology, oncology, pediatrics, and respiratory diseases, with several products passing consistency evaluations[39]. - The company established a key laboratory for traditional Chinese medicine quality research, enhancing its R&D capabilities[51]. - R&D investment amounted to 147 million yuan, an increase of 19.17% year-on-year, representing 1.15% of total revenue and 4.23% of pharmaceutical industry revenue[76]. - The company has a total of 9 PhD graduates and 290 master's degree holders among its employees[180]. Market Expansion and Strategy - The company plans to continue expanding its market presence and invest in new product development to drive future growth[35]. - The company is focusing on core brands and expanding key product promotions to adjust the gross profit structure in response to market changes[57]. - The company is actively managing costs and budgets while enhancing market management to address fluctuations in gross margins for certain products[57]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 2 billion RMB for potential deals[158]. - The company aims to achieve a revenue of 14 billion yuan in 2022, representing a year-on-year growth of 9.36%[132]. Employee Compensation and Management - The total pre-tax remuneration for all senior management during the reporting period amounted to 2,101,670 RMB[153]. - The performance-based compensation for senior management in 2021 is pending approval from the board before distribution[165]. - The company has implemented a market-oriented compensation system for employees and senior management, emphasizing performance-based incentives and cost control[181]. - The company has established a stock option and restricted stock incentive plan to align management's interests with long-term performance goals[181]. - The total number of shares held by all senior management at the beginning of the year was 505,500, and at the end of the year was 4,855,500, reflecting a significant increase[153]. Financial Flexibility and Investments - The company plans to apply for bank loans to support its operational needs and future growth[144]. - The company plans to apply for a comprehensive credit facility from banks for 2021, indicating a strategy for financial flexibility[171]. - The company is leveraging capital and internal entrepreneurship mechanisms to accelerate growth through mergers and acquisitions[131]. - The company has proposed to apply for bank loans in multiple board meetings throughout the reporting period[166]. Operational Efficiency - The company has implemented refined management processes and optimized resource allocation to improve operational efficiency and management capabilities[47]. - The company is committed to improving its governance structure and protecting shareholder rights, particularly for minority shareholders[137]. - The company has established performance contracts for senior management based on operational and management indicators[165]. - The company is implementing comprehensive capacity optimization and lean management to improve manufacturing excellence[131].

Financial Performance - The company's operating revenue for Q3 2021 reached ¥3,333,602,912.67, representing a year-on-year increase of 17.39%[7] - The net profit attributable to shareholders of the listed company was ¥144,423,485.03 for the quarter, with a year-to-date net profit of ¥486,512,183.61[7] - The basic earnings per share for the quarter was ¥0.06, while the diluted earnings per share was also ¥0.06[10] - Total operating revenue for the first three quarters of 2021 reached ¥9,739,388,256.55, a 27.4% increase from ¥7,649,073,314.94 in the same period of 2020[24] - Net profit for the first three quarters of 2021 was ¥529,217,376.22, compared to a net loss of ¥337,526,259.51 in the same period of 2020[27] - Earnings per share for the first three quarters of 2021 were ¥0.20, significantly higher than ¥0.02 in the previous year[29] - The company reported a significant increase in undistributed profits, rising to ¥1,203,378,547.45 from ¥769,229,810.25 in the previous year[24] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥12,307,962,788.84, reflecting a 3.89% increase compared to the end of the previous year[10] - Current assets totaled RMB 8,256,715,961.44, up from RMB 7,807,872,198.48 year-over-year, reflecting a growth of approximately 5.74%[19] - Total liabilities were RMB 7,801,181,436.74, a slight decrease from RMB 7,858,964,273.05, indicating a reduction of about 0.73%[22] - The company's total equity increased to RMB 4,506,781,352.10 from RMB 3,988,570,179.03, representing a growth of about 12.99%[22] - The total liabilities and equity of the company amounted to ¥12,307,962,788.84, compared to ¥11,847,534,453.08 in the previous year[24] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥156,132,240.91, indicating a significant cash flow pressure[10] - Operating cash inflow for the first nine months reached ¥9,141,618,654.76, an increase of 6.6% compared to ¥8,580,795,005.33 in the previous year[32] - Net cash outflow from operating activities was ¥156,132,240.91, worsening from a net outflow of ¥72,943,528.85 in the same period last year[32] - Cash inflow from financing activities amounted to ¥1,210,949,527.45, up from ¥1,138,818,458.33 in the same period last year[34] - The ending cash and cash equivalents balance was ¥827,704,355.66, down from ¥1,242,135,631.00 at the end of the previous year[34] Operational Efficiency - The weighted average return on equity increased by 12.42 percentage points to 3.75% for the quarter[10] - The company has actively expanded its market presence and adjusted its product structure, leading to significant revenue growth compared to the same period last year[12] - The company plans to continue enhancing management efficiency and capacity utilization to further reduce costs and improve profitability[12] - The company reported a significant increase in cash received from operating activities, indicating improved operational efficiency[32] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 113,941, with the largest shareholder holding 46.59% of the shares[14] - The company's total equity attributable to shareholders reached ¥3,927,243,755.67, an increase from ¥3,479,645,542.97 year-over-year[24] Expenses - Total operating costs for the first three quarters of 2021 were ¥9,169,764,055.18, up 17.1% from ¥7,830,643,271.45 in the previous year[24] - Research and development expenses decreased to ¥61,878,123.07 from ¥74,599,650.12, indicating a focus on cost management[24] - The company experienced a notable increase in sales expenses, which rose to ¥881,806,024.22 from ¥653,552,480.68[24] Other Financial Metrics - Non-recurring gains and losses for the quarter totaled ¥10,381,028.24, with government subsidies contributing ¥7,488,596.09[10] - The company reported a decrease in credit impairment losses, which improved to -¥27,258,906.69 from -¥180,383,073.82 year-over-year[27] - The company reported a significant other comprehensive loss of approximately 1.74 billion[40]

Financial Performance - The company's operating revenue for the first half of 2021 reached ¥6,405,785,343.88, representing a 33.19% increase compared to ¥4,809,380,177.49 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was ¥342,088,698.57, a significant recovery from a loss of ¥333,302,234.51 in the previous year[23]. - The net cash flow from operating activities was ¥159,437,052.40, improving from a negative cash flow of ¥166,711,071.07 in the same period last year[23]. - The basic earnings per share for the first half of 2021 was ¥0.14, recovering from a loss of ¥0.13 in the same period last year[24]. - The weighted average return on net assets was 9.42%, a recovery from -7.56% in the previous year[24]. - The net profit for the first half of 2021 was ¥365,615,681.29, a significant recovery from a net loss of ¥312,721,712.23 in the first half of 2020[150]. - The total comprehensive income attributable to the parent company for the first half of 2021 was CNY 340,062,278.10, compared to a loss of CNY 1,045,344,052.21 in the first half of 2020[152]. Revenue and Cost Analysis - The company's operating costs increased by 30.33% to ¥4,926,062,404.91 from ¥3,779,564,910.36 year-on-year, driven by increased sales volume[55]. - The total operating costs amounted to ¥6,078,569,019.92, up from ¥4,957,933,116.16, reflecting a growth of 22.6%[146]. - Sales expenses rose significantly by 49.11% to ¥595,312,026.87, attributed to higher promotional costs for market expansion[55]. Asset and Liability Overview - The total assets of the company at the end of the reporting period were ¥12,041,241,934.00, a 1.64% increase from ¥11,847,534,453.08 at the end of the previous year[23]. - The company's cash and cash equivalents at the end of the period amounted to ¥1,055,709,720.44, representing 8.77% of total assets, an increase of 17.69% from the previous year[58]. - The total liabilities rose to ¥5,684,499,053.51, up from ¥5,611,171,009.10, indicating a growth of 1.3%[146]. - The company's total liabilities decreased to CNY 7,743,816,564.78 from CNY 7,858,964,273.05, a decline of about 1.46%[139]. Research and Development - The company has 20 product projects in the research stage, with 4 new product projects initiated during the reporting period[47]. - Research and development expenses for the first half of 2021 were ¥41,965,014.24, down from ¥54,154,695.03 in the same period last year, a decrease of 22.5%[150]. - The company is developing 3 health products in its newly established health research institute, achieving preliminary progress[47]. Market Position and Strategy - The company focused on target management and enhanced team specialization, leading to significant sales revenue growth in the reporting period[25]. - The company is focused on leveraging its brand and product advantages to enhance market competitiveness and drive growth[39]. - The company actively expanded new sales channels and optimized management processes to improve operational efficiency during the pandemic[35]. Environmental and Social Responsibility - The company has implemented pollution prevention facilities, including wastewater treatment systems with a design capacity of 20,000 tons per day at the main plant[84]. - The company donated calcium supplements valued at 16.034 million yuan to support health initiatives for disadvantaged groups[96]. - The company is actively involved in poverty alleviation and rural revitalization efforts, aligning with national strategies[96]. Corporate Governance and Management Changes - The company has undergone significant management changes, with new appointments in key positions, including the election of a new chairman and several directors[72]. - The company appointed new executives, including Liang Chen, Wang Penghao, Wang Haisheng, and Lu Chuanyou as vice presidents[75]. - The company’s independent directors and board members were elected during the first extraordinary shareholders' meeting of 2021[75]. Future Outlook - The company plans to introduce several new products and enhance its product pipeline, with multiple projects expected to reach milestone stages in the second half of the year[52]. - The company plans to continue focusing on market expansion and new product development to sustain growth momentum in the upcoming quarters[150].

2021 年第一季度报告 公司代码：600664 公司简称：哈药股份 哈药集团股份有限公司 2021 年第一季度报告 1 / 19 2021 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 19 2021 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人徐海瑛、主管会计工作负责人刘波及会计机构负责人（会计主管人员）魏巍保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------------------------|-------------------|----------- ...

Financial Performance - In 2020, the company's operating revenue was CNY 10,788,456,548.75, a decrease of 8.76% compared to CNY 11,824,561,675.04 in 2019[24] - The net profit attributable to shareholders of the listed company for 2020 was a loss of CNY 1,077,699,405.63, a significant decline of 2,030.94% from a profit of CNY 55,812,116.14 in 2019[24] - The net cash flow from operating activities was a negative CNY 728,154,257.63, worsening by 155.55% compared to a negative CNY 284,938,535.31 in 2019[24] - The net assets attributable to shareholders of the listed company decreased by 36.23% to CNY 3,479,645,542.97 at the end of 2020 from CNY 5,456,565,308.41 at the end of 2019[24] - Total assets at the end of 2020 were CNY 11,847,534,453.08, down 5.24% from CNY 12,502,530,832.80 at the end of 2019[24] - The company reported a net profit excluding non-recurring gains and losses of CNY -714,935,040.48 in 2020, compared to CNY -12,148,243.03 in 2019, reflecting a decline of 5,785.09%[24] - Basic earnings per share for 2020 was -0.43 CNY, a decrease of 2,250.00% compared to 0.02 CNY in 2019[25] - The weighted average return on equity for 2020 was -24.12%, a decrease of 25.06 percentage points from 0.94% in 2019[25] Revenue and Sales - Total revenue for Q4 2020 was 3,139,383,233.81 CNY, showing an increase compared to Q3 2020 revenue of 2,839,693,137.45 CNY[28] - The net profit attributable to shareholders for Q4 2020 was -705,035,677.48 CNY, worsening from -39,361,493.64 CNY in Q3 2020[28] - The company reported a revenue of 248.57 billion CNY in 2020, with a year-on-year growth of 4.5%[38] - The pharmaceutical manufacturing segment generated revenue of 2.77 billion RMB, while the pharmaceutical commercial segment accounted for 7.97 billion RMB[51] - Revenue from chemical preparations is 1,573,973,488.82 CNY, with a year-over-year decrease of 29.67%[54] - Revenue from traditional Chinese medicine is 625,552,134.34 CNY, with a year-over-year increase of 8.81%[54] - The revenue from wholesale medical customers is 4,984,445,403.19 CNY, with a year-over-year decrease of 14.35%[54] - The revenue from retail customers is 1,281,434,176.26 CNY, with a year-over-year increase of 11.86%[54] Operational Efficiency - The company has implemented three institutional reforms to optimize management processes and enhance operational efficiency[38] - The company implemented a three-system reform to enhance management efficiency and optimize personnel allocation, which positively impacted production control capabilities[45] - The company has established six DTP specialty pharmacies to improve chronic disease management and enhance patient services[50] - The company has expanded its professional team and business channels, increasing the number of clients in the national policy product category to over 2,800, a growth of 50%[50] - The company has optimized its channel inventory by the end of the year, leading to a healthier sales environment[61] Research and Development - The company has a product line of 347 specifications, focusing on therapeutic areas such as anti-infection, cardiovascular, and oncology[35] - The company is focusing on enhancing its product structure in key therapeutic areas such as neurology, oncology, and pediatrics, while also exploring high-end formulations[46] - The company has made progress in product development, with several products passing consistency evaluations, including Amoxicillin capsules and Ibuprofen granules[46] - The company’s R&D investment amounted to 36,646.47 million RMB, representing 3.37% of operating revenue and 6.59% of net assets, with a capitalization ratio of 83.34%[103] - The company’s R&D investment as a percentage of operating revenue during the reporting period was 1.15%, while the ratio of R&D investment to net assets was 3.10%[103] Market Position and Strategy - The company has established strategic partnerships with Peking University and Harbin Institute of Technology for collaborative research and development[39] - The company has received multiple awards, including "Top Ten Brands in China's Pharmaceutical Industry" and "Most Influential Brand in China's Pharmaceutical Industry"[39] - The company aims to enhance its core competitiveness through brand, product, quality, research, and talent advantages[39] - The company is actively pursuing partnerships with major e-commerce platforms to expand online sales channels and improve market reach[46] - The company plans to enhance marketing capabilities and improve brand influence to strengthen market competitiveness[122] Environmental and Social Responsibility - The company reported actual wastewater discharge levels significantly below permitted limits, with chemical oxygen demand at 43.05 mg/L against a limit of 500 mg/L[158] - The company aims to integrate poverty alleviation with rural revitalization efforts, focusing on sustainable agricultural projects[156] - The company has established the "Hayao Public Welfare Foundation" to connect quality resources and promote social responsibility through various charitable activities[157] - The company donated a total of RMB 172,300 in materials to support poverty alleviation efforts, including medical supplies valued at RMB 18,700 during the pandemic[152] - The company has been recognized for its contributions to poverty alleviation, with team leader Xu Liting awarded honors for outstanding service[153] Risks and Challenges - The company faces risks related to industry policies, environmental regulations, product quality, research and development, raw material procurement, and the ongoing impact of the COVID-19 pandemic[129][130] - The company is prepared to respond to extreme market conditions and will continue to monitor the progress of the COVID-19 pandemic[133] - The company has committed to improving product quality control and adhering to production standards to mitigate risks associated with product quality[133] - The average profit margin in the pharmaceutical industry has declined due to policy impacts and rising raw material prices[57] Shareholder and Equity Management - The company completed the repurchase and cancellation of 64,000 restricted shares on December 4, 2020, reducing the total shares from 2,507,019,076 to 2,506,955,076[176] - The total number of ordinary shareholders increased from 125,558 to 131,164 during the reporting period[179] - The top ten shareholders hold a total of 1,373,000,000 shares, representing approximately 54.68% of the total shares[179] - The company has no significant changes in its equity structure during the reporting period[182] - The company has not disclosed any significant changes in its stock incentive plans, indicating a consistent approach to employee motivation[141]

证券代码:600664 证券简称:哈药股份 编号:临 2020-052 哈药集团股份有限公司 关于参加投资者网上集体接待日活动的公告 | --- | --- | --- | |-------------------------------------------------------------------------|-------|------------------------------------------------------------------| | | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | | | | | 为进一步加强与投资者的互动交流，哈药集团股份有限公司（以 | | 下简称"公司"）将参加由黑龙江省上市公司协会、深圳市全景网络 | | | | 有限公司共同举办的"黑龙江省上市公司 2020 | | 年度投资者网上集体 | | 接待日"活动，现将有关事项公告如下： | | | | | | 本次集体接待日活动将通过深圳市全景网络有限公司提供的互 | | ...